Skip to main content
. 2010 Mar-Apr;2(2):129–136. doi: 10.4161/mabs.2.2.11221

Table 3.

Analysis of the gastric-cancer subgroup (pivotal trial)

Gastric-cancer subgroup (n = 66) Puncture free survival Time to next therapeutic puncture Overall survival
Catumaxomab group (n = 46) 44 days 118 days 71 days
Control group (n = 20) 15 days 15 days 44 days
p value <0.0001 <0.0001 0.0313
Hazard ratio (95% CI) 0.289 (0.151; 0.554) 0.143 (0.057; 0.359) 0.469 (0.232; 0.951)